

## NOTICE OF CHANGE IN CORPORATE STRUCTURE

### Pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations

**1. The names of the parties to the transaction:**

Lancaster Resources Inc. (formerly, NeonMind Biosciences Inc.) (the “**Company**”), 1405306 B.C. Ltd., a wholly owned subsidiary of the Company (“**Subco**”), and Lancaster Lithium Inc. (“**Lancaster Lithium**”)

**2. A description of the transaction:**

On June 9, 2023, the Company completed a reverse takeover transaction pursuant to which Subco and Lancaster Lithium amalgamated to form a new entity (“**Amalco**”) under the *Business Corporations Act* (British Columbia) (the “**Amalgamation**”). Under the terms of the Amalgamation, (i) each shareholder of Lancaster Lithium received one common share of the Company for each common share of Lancaster Lithium held by them, (ii) each holder of warrants to purchase common shares of Lancaster Lithium received replacement warrants to purchase common shares of the Company on substantially the same terms, (iii) each holder of broker warrants to purchase common shares of Lancaster Lithium received replacement warrants to purchase common shares of the Company on substantially the same terms, and (iv) each holder of options to purchase common shares of Lancaster Lithium received replacement options to purchase common shares of the Company on substantially the same terms. As a result of the transactions described above, the Company became the parent company of Amalco. Just prior to the completion of the Amalgamation, the Company changed its name to “Lancaster Resources Inc.” on June 7, 2023. The common shares of the Company began trading on the Canadian Securities Exchange (the “**CSE**”) under the new symbol “**LCR**” on June 14, 2023.

**3. The effective date of the transaction:**

June 9, 2023 / June 14, 2023

**4. The name of each party, if any, that ceased to be a reporting issuer after the transaction and of each continuing entity:**

N/A

**5. The date of the reporting issuer’s first financial year-end after the transaction if Section 4.9(a) or 4.9(b)(ii) of National Instrument 51-102 applies:**

March 31, 2023

**6. The periods, including the comparative periods, if any, of the interim financial reports and the annual financial statements required to be filed for the reporting issuer's first financial year after the transaction if Section 4.9(a) or 4.9(b)(ii) of National Instrument 51-102 applies:**

The Company will be required to file (i) annual consolidated financial statements for the year ending March 31, 2023 (with comparatives for the year ended March 31, 2022); (ii) consolidated financial statements for the three month period ending June 30, 2023 (with comparatives for the three months ended June 30, 2022), (iii) interim consolidated financial statements for the six month period ending September 30, 2023 (with comparatives for the six months ended September 30, 2022), and (iv) interim consolidated financial statements for the nine month period ending December 31, 2023 (with comparatives for the nine months ended December 31, 2022).

**7. What document were filed under National Instrument 51-102 that described the transaction and where those documents can be found in electronic format, if Section 4.9(a) or 4.9(b)(ii) of National Instrument 51-102 applies:**

The following documents which describe the transactions contemplated herein were filed and are available on SEDAR at [www.sedar.com](http://www.sedar.com): (i) the merger agreement between the Company, Subco and Lancaster Lithium dated March 21, 2023; (ii) the news releases of the Company dated December 14, 2022, March 23, 2023, June 9, 2023, and June 14, 2023; (iii) the material change reports of the Company dated December 21, 2022 and March 31, 2023, and (iv) the CSE Form 2A Listing Statement of the Company dated June 9, 2023.

Dated: June 20, 2023